Carbon monoxide activates large-conductance calcium-activated potassium channels of human cardiac fibroblasts through various mechanisms

Hyemi Bae,Taeho Kim,Inja Lim
DOI: https://doi.org/10.4196/kjpp.2021.25.3.227
2021-05-01
Abstract:Carbon monoxide (CO) is a cardioprotectant and potential cardiovascular therapeutic agent. Human cardiac fibroblasts (HCFs) are important determinants of myocardial structure and function. Large-conductance Ca<sup>2+</sup>-activated K<sup>+</sup> (BK) channel is a potential therapeutic target for cardiovascular disease. We investigated whether CO modulates BK channels and the signaling pathways in HCFs using whole-cell mode patch-clamp recordings. CO-releasing molecules (CORMs; CORM-2 and CORM-3) significantly increased the amplitudes of BK currents (<i>IBK</i>). The CO-induced stimulating effects on <i>IBK</i> were blocked by pre-treatment with specific nitric oxide synthase (NOS) blockers (L-N<sup>G</sup>-monomethyl arginine citrate and L-N<sup>G</sup>-nitroarginine methyl ester). 8-bromo-cyclic GMP increased <i>IBK</i>. KT5823 (inhibits PKG) or ODQ (inhibits soluble guanylate cyclase) blocked the CO-stimulating effect on <i>IBK</i>. Moreover, 8-bromo-cyclic AMP also increased <i>IBK</i>, and pre-treatment with KT5720 (inhibits PKA) or SQ22536 (inhibits adenylate cyclase) blocked the CO effect. Pre-treatment with Nethylmaleimide (a thiol-alkylating reagent) also blocked the CO effect on <i>IBK</i>, and DLdithiothreitol (a reducing agent) reversed the CO effect. These data suggest that CO activates <i>IBK</i> through NO <i>via</i> the NOS and through the PKG, PKA, and <i>S</i>-nitrosylation pathways.
pharmacology & pharmacy,physiology
What problem does this paper attempt to address?